PatenSee Initiates 1st In-Human Trial with its Contactless Imaging Surveillance System for Patients Undergoing Hemodialysis

February 16, 2021

PatenSee, a developer of a contact-free surveillance tool designed to identify asymptomatic stenosis, today announced the initiation of its first-in-human clinical trial for its machine vision-based surveillance system.

PatenSee notes the trial, led by Prof. Benaya Rozen-zvi, director of the Institute for Nephrology and Hypertension at Rabin Medical Center, will evaluate the system’s ability to perform contact-free surveillance of fistula stenosis similar to a nurse’s physical exam of hemodialysis patients.

“The clinical data we collect will be the first of its kind and will provide a critical step towards a reliable contact-free early detection tool for fistula stenosis,” explained Prof. Benaya Rozen-zvi. “Keeping the fistula open is a major clinical need, and early detection of stenosis allows for both simpler treatment and better prognosis for the patient.”

He added, “The non-invasive, contactless nature of PatenSee’s system adds another important benefit for both in-patient settings as well as in homecare in the future. The ability to assess patients effectively at a distance has become particularly important for both patients and clinicians during the worldwide COVID-19 pandemic.”

“The trial initiation is a significant milestone for PatenSee,” said Dr. Gal Goshen, CEO of PatenSee. “We are excited to complete all bench testing required to bring the system to the clinical stage and look forward to providing a reliable early detection system for fistula stenosis that can save lives, reduce suffering and address a challenge currently costing for payers and providers millions of dollars every year.”

Collaboration with the medical doctors and nurses involved in the trial enabled easy integration of PatenSee’s system into the patient workflow of the dialysis center. The system is used in the pre-dialysis waiting room with minimal to no intervention of the medical staff and no interruption to the workflow.

SourcePatenSee
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version